DEXON Pharmaceuticals Co., Ltd. (located in Chuo-ku, Tokyo; represented by Shoji Koga, CEO) has recently acquired a patent (Patent No. 7007754) for SGF, a composition that effectively inhibits ACE2 binding for virus prevention (including COVID-19 caused by the novel coronavirus). In preparation for the spread of infections due to the Omicron variant of the novel coronavirus, the company will provide this composition to medical collaboration institutions (for private medical services).
The Spike-ACE2 Binding Inhibitory Effect of SGF-EVs
■Mechanism of Action
By inhaling SGF through an inhaler, the binding between viruses that utilize ACE2 as a receptor, such as COVID-19, and ACE2 is inhibited. Specifically, SGF contains exosomes expressing ACE2 derived from deciduous tooth pulp stem cells. Using these exosomes, it is possible to inhibit or block the attachment of SARS-CoV-2 to host cells.
Previously, it was reported that using ACE2-negative MSCs (mesenchymal stem cells) was preferable for treating COVID-19. However, we have discovered that using ACE2-positive compositions can prevent COVID-19 in healthy individuals. As a result, we have invented a more effective composition.
■Method of Providing to Medical Institutions
The SGF used for prevention is prepared as an in-house formulation at medical collaboration institutions and administered via inhalation or nasal administration using an inhaler.
Due to the nature of in-house formulations, it is necessary for individuals to visit medical collaboration institutions, although the medical procedure is minimally invasive. To provide services nationwide, remote consultations will be conducted, and SGF along with inhalers will be delivered to the homes of those who wish to receive them.
■Safety
SGF has been used in private medical services at medical collaboration institutions (represented by Shoji Koga, Solaria Clinic Group) since 2017, and its safety has been proven to be extremely high based on the treatment of over 2,500 individuals (as of October 2021) without any serious side effects.
■The Background of This Announcement
The announcement at this time stems from the efforts of Shoji Koga, CEO of DEXON Pharmaceuticals, who has been conducting clinical and research activities at medical collaboration institutions since the emergence of COVID-19 in 2019, resulting in the acquisition of patents and leading to this announcement.
■Medical Institutions Implementing Preventive Measures
Solaria Clinic Group
5F Ginza Willow Avenue BLDG, 1-5-8 Ginza, Chuo-ku, Tokyo 104-0061
TEL: 03-5524-1850
Email： info@ginza-solaria.com
【Company Overview】
Company Name: DEXON Pharmaceuticals Co., Ltd.
Representative: Shoji Koga, CEO
Address: 3F Hulic Yaesu Dori Building, 3-5-12 Nihonbashi, Chuo-ku, Tokyo
Established: April 30, 2020
Capital: 16.5 million yen
